Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.
Stem Cells Transl Med
; 9(12): 1488-1494, 2020 12.
Article
in English
| MEDLINE | ID: covidwho-718380
ABSTRACT
Sepsis is defined as life-threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS-CoV-2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently being tested, including mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in a few clinical trials, appear well-tolerated and promising, but many questions remain unanswered.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Shock, Septic
/
Sepsis
/
Mesenchymal Stem Cell Transplantation
/
COVID-19
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Animals
/
Humans
Language:
English
Journal:
Stem Cells Transl Med
Year:
2020
Document Type:
Article
Affiliation country:
Sctm.20-0239
Similar
MEDLINE
...
LILACS
LIS